Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bolt Biotherapeutics (BOLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BOLT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.35% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.68M USD | Price to earnings Ratio - | 1Y Target Price 1.12 |
Price to earnings Ratio - | 1Y Target Price 1.12 | ||
Volume (30-day avg) 124648 | Beta 0.94 | 52 Weeks Range 0.38 - 1.40 | Updated Date 04/2/2025 |
52 Weeks Range 0.38 - 1.40 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.65 |
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate -0.35 | Actual -0.42 |
Profitability
Profit Margin - | Operating Margin (TTM) -887.33% |
Management Effectiveness
Return on Assets (TTM) -32.88% | Return on Equity (TTM) -74.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -7429897 | Price to Sales(TTM) 1.91 |
Enterprise Value -7429897 | Price to Sales(TTM) 1.91 | ||
Enterprise Value to Revenue 270.65 | Enterprise Value to EBITDA 0.93 | Shares Outstanding 38339700 | Shares Floating 27481128 |
Shares Outstanding 38339700 | Shares Floating 27481128 | ||
Percent Insiders 5.08 | Percent Institutions 48.15 |
Analyst Ratings
Rating 3 | Target Price 1.75 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bolt Biotherapeutics
Company Overview
History and Background
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer. It was founded in 2015 and went public in 2021. The company's focus is on harnessing the power of the immune system to fight cancer.
Core Business Areas
- Immuno-oncology: Development of Boltbodyu2122 Immune-Stimulating Antibody Conjugates (ISACs), a novel class of immunotherapeutics that direct the immune system to eliminate tumors.
Leadership and Structure
Dr. Randall C. Schatzinger is the President and CEO. The company has a typical biopharmaceutical structure with departments focused on research, development, clinical trials, and corporate operations.
Top Products and Market Share
Key Offerings
- BDTX-1535: BDTX-1535 is Bolt's lead Boltbody ISAC product candidate, targeting solid tumors expressing HER2. As a clinical-stage asset, it currently generates no revenue. Competitors include companies developing HER2-targeted therapies, such as Roche (Herceptin, Kadcyla, Perjeta) and AstraZeneca (Enhertu).
- BDT101: Is in Clinical development to treat cancer. This product is also in clinical development, and is still not available in the market. Competitors: Other companies developing TLR7/8 agonists, for example Dynavax
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth due to the increasing success of immunotherapies in treating various cancers. Competition is intense, with numerous companies developing novel approaches.
Positioning
Bolt Biotherapeutics is positioned as an innovator in the ISAC space, aiming to differentiate itself through its unique Boltbody platform. Its competitive advantage lies in the potential to stimulate a targeted immune response against tumors.
Total Addressable Market (TAM)
The immuno-oncology market is estimated to be worth hundreds of billions of dollars. Bolt Biotherapeutics is positioned to capture a portion of this market with successful development and commercialization of its Boltbody ISACs.
Upturn SWOT Analysis
Strengths
- Novel Boltbody ISAC platform
- Targeted immune stimulation
- Experienced leadership team
- Strong preclinical and clinical data for lead candidates
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial risks and potential for failure
- Dependence on successful development of lead candidates
- Lack of established commercial infrastructure
Opportunities
- Potential for strategic partnerships with larger pharmaceutical companies
- Expansion of Boltbody platform to new cancer targets
- Advancements in immunotherapy technologies
- Positive clinical trial results leading to regulatory approvals
Threats
- Competition from established immunotherapy companies
- Unfavorable regulatory changes
- Unexpected safety issues in clinical trials
- Failure to secure sufficient funding
Competitors and Market Share
Key Competitors
- RHHBY
- AZN
- MRTX
- NKTR
Competitive Landscape
Bolt Biotherapeutics faces significant competition from established pharmaceutical companies with greater resources and existing marketed products. However, its novel Boltbody ISAC platform offers a potential competitive advantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth has been characterized by preclinical and early-stage clinical development progress.
Future Projections: Future growth is dependent on positive clinical trial results and potential regulatory approvals of its lead candidates. Analyst estimates vary, but generally reflect optimism regarding the potential of the Boltbody ISAC platform.
Recent Initiatives: Recent initiatives include advancing BDTX-1535 through clinical trials and expanding the Boltbody platform to new cancer targets.
Summary
Bolt Biotherapeutics is a clinical-stage company with a promising immuno-oncology platform. Its success hinges on the clinical advancement and eventual approval of its Boltbody ISAC candidates. The company faces competition from larger players in the market and needs to effectively manage its financial resources. Positive clinical trial results will be crucial for driving future growth and shareholder value. They are a risky and speculative investment given there are no products available for sale yet.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
NKTR
Nektar Therapeutics
NKTR
Nektar Therapeutics
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bolt Biotherapeutics
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO, CFO, President, Secretary & Director Mr. William P. Quinn | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.boltbio.com |
Full time employees 52 | Website https://www.boltbio.com | ||
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.